MapLight Therapeutics (MPLT) CMO reports RSU tax withholding of 44,616 shares

Rhea-AI Filing Summary

MapLight Therapeutics Chief Medical Officer Erin Pennock Foff reported a tax-related share withholding tied to restricted stock units. On January 27, 2026, 44,616 shares of MapLight voting common stock were withheld at $17.98 per share to cover tax obligations, leaving 390,475 shares beneficially owned directly. The remaining securities are still subject to a 180-day IPO lock-up following the final prospectus date of October 26, 2025, limiting sales or transfers during that period.

Insider Trade Summary

Net Seller: 44,616 shares

Net Sell 1 txn

Insider Foff Erin Pennock

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Voting Common Stock	44,616	$17.98	$802K

Holdings After Transaction: Voting Common Stock — 390,475 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

FAQ

What insider transaction did MPLT’s Chief Medical Officer report on January 27, 2026?

The Chief Medical Officer, Erin Pennock Foff, reported a tax-related transaction where 44,616 shares of MapLight voting common stock were withheld at $17.98 per share to satisfy tax obligations from restricted stock unit settlement.

How many MPLT shares does Erin Pennock Foff own after the reported Form 4 transaction?

After the transaction, Erin Pennock Foff beneficially owns 390,475 shares of MapLight voting common stock directly. This reflects the position following the 44,616-share withholding to cover tax obligations upon settlement of restricted stock unit awards.

Was the MPLT insider transaction a discretionary sale or tax withholding event?

The transaction was a tax withholding event, not a discretionary open-market sale. MapLight withheld 44,616 shares to cover tax obligations arising from the settlement of restricted stock unit awards granted to Chief Medical Officer Erin Pennock Foff.

What price per share was used for the MPLT tax withholding on restricted stock units?

The shares withheld for tax purposes were valued at $17.98 per share. This price was applied to the 44,616 MapLight voting common stock shares used to satisfy tax withholding obligations tied to restricted stock unit settlement.

Is the MPLT Chief Medical Officer still subject to an IPO lock-up on shares?

Yes. The securities retained by Erin Pennock Foff remain subject to a 180-day lock-up agreement following the final IPO prospectus dated October 26, 2025, restricting most direct or indirect sales or transfers of MapLight securities during that period.

What role does Erin Pennock Foff hold at MapLight Therapeutics, Inc. (MPLT)?

Erin Pennock Foff serves as Chief Medical Officer of MapLight Therapeutics, Inc. This officer position is disclosed in the insider ownership section, where she reports beneficial ownership and the tax-related withholding transaction involving MapLight voting common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/29/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foff Erin Pennock

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	01/27/2026		F		44,616(1)	D	$17.98	390,475	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.